Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C

被引:117
作者
Hengst, Julia [1 ]
Falk, Christine Susanne [2 ,3 ,4 ]
Schlaphoff, Verena [1 ]
Deterding, Katja [1 ]
Manns, Michael Peter [1 ,3 ,4 ]
Cornberg, Markus [1 ,4 ]
Wedemeyer, Heiner [1 ,2 ,3 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Hannover Med Sch, Inst Transplant Immunol, Hannover, Germany
[3] Hannover Med Sch, Integrated Res & Treatment Ctr, Hannover, Germany
[4] German Ctr Infect Res, Hannover, Germany
关键词
HCV; chronic hepatitis C; DAA; direct-acting antiviral; cytokines; chemokines; soluble immune mediators; cirrhosis; T-CELL RESPONSES; VIRAL-HEPATITIS; INFECTION; THERAPY; SOFOSBUVIR; CYTOKINES/CHEMOKINES; EXPRESSION; RIBAVIRIN; CIRRHOSIS; DYNAMICS;
D O I
10.1093/infdis/jiw457
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Persistent infection with hepatitis C virus (HCV) causes profound alterations of the cytokine and chemokine milieu in peripheral blood. However, it is unknown to what extend these alterations affect the progression of liver disease and whether HCV clearance normalizes soluble inflammatory mediators. Methods. We performed multianalyte profiling of 50 plasma proteins in 28 patients with persistent HCV infection and advanced stages of liver fibrosis or cirrhosis and 20 controls with fatty liver disease. The patients were treated for 24 weeks with sofosbuvir and ribavirin and underwent sampling longitudinally. Ten patients experienced viral relapse after treatment cessation. Results. The cytokine and chemokine expression pattern was markedly altered in patients with chronic HCV infection as compared to healthy controls and patients with nonalcoholic steatohepatitis. Distinct soluble factors were associated with the level of fibrosis/cirrhosis, viral replication, or treatment outcome. The baseline expression level of 10 cytokines distinguished patients with a sustained viral response from those who experienced viral relapse. While the majority of upregulated analytes declined during and after successful therapy, HCV clearance did not lead to a restoration of parameters that were suppressed. Conclusions. Chronic HCV infection appears to disrupt the milieu of soluble inflammatory mediators even after viral clearance. Thus, HCV cure does not lead to complete immunological restitution.
引用
收藏
页码:1965 / 1974
页数:10
相关论文
共 32 条
[1]   The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection [J].
Barnes, E ;
Harcourt, G ;
Brown, D ;
Lucas, M ;
Phillips, R ;
Dusheiko, G ;
Klenerman, P .
HEPATOLOGY, 2002, 36 (03) :743-754
[2]   Cytokines and persistent viral infections [J].
Beltra, Jean-Christophe ;
Decaluwe, Helene .
CYTOKINE, 2016, 82 :4-15
[3]   Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection [J].
Carlin, Aaron F. ;
Aristizabal, Paula ;
Song, Qinghua ;
Wang, Huan ;
Paulson, Matthew S. ;
Stamm, Luisa M. ;
Schooley, Robert T. ;
Wyles, David L. .
HEPATOLOGY, 2015, 62 (04) :1047-1058
[4]   Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply [J].
Deterding, K. ;
Schlevogt, B. ;
Port, K. ;
Cornberg, M. ;
Wedemeyer, H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (04) :546-547
[5]   Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies [J].
Deterding, K. ;
Siederdissen, C. Hoener Zu ;
Port, K. ;
Solbach, P. ;
Sollik, L. ;
Kirschner, J. ;
Mix, C. ;
Cornberg, J. ;
Worzala, D. ;
Mix, H. ;
Manns, M. P. ;
Cornberg, M. ;
Wedemeyer, H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) :889-901
[6]   The ABCs of Viral Hepatitis That Define Biomarker Signatures of Acute Viral Hepatitis [J].
Duffy, Darragh ;
Mamdouh, Rasha ;
Laird, Melissa ;
Soneson, Charlotte ;
Le Fouler, Lenaig ;
El-Daly, Mai ;
Casrouge, Armanda ;
Decalf, Jeremie ;
Abbas, Amal ;
Eldin, Noha Sharaf ;
Fontes, Magnus ;
Abdel-Hamid, Mohamed ;
Mohamed, Mostafa K. ;
Rafik, Mona ;
Fontanet, Arnaud ;
Albert, Matthew L. .
HEPATOLOGY, 2014, 59 (04) :1273-1282
[7]   Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis [J].
Foster, Graham R. ;
Irving, William L. ;
Cheung, Michelle C. M. ;
Walker, Alex J. ;
Hudson, Benjamin E. ;
Verma, Suman ;
McLauchlan, John ;
Mutimer, David J. ;
Brown, Ashley ;
Gelson, William T. H. ;
MacDonald, Douglas C. ;
Agarwal, Kosh .
JOURNAL OF HEPATOLOGY, 2016, 64 (06) :1224-1231
[8]   Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C [J].
Gane, Edward J. ;
Stedman, Catherine A. ;
Hyland, Robert H. ;
Ding, Xiao ;
Svarovskaia, Evguenia ;
Symonds, William T. ;
Hindes, Robert G. ;
Berrey, M. Michelle .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (01) :34-44
[9]   Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection [J].
Gisa, A. ;
Suneetha, P. V. ;
Behrendt, P. ;
Pischke, S. ;
Bremer, B. ;
Falk, C. S. ;
Manns, M. P. ;
Cornberg, M. ;
Wedemeyer, H. ;
Kraft, A. R. M. .
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (04) :305-315
[10]   Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3 [J].
Golden-Mason, Lucy ;
Hurtado, Christine E. Waasdorp ;
Cheng, Linling ;
Rosen, Hugo R. .
CLINICAL IMMUNOLOGY, 2015, 158 (01) :114-125